Methods and fluorinated compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH—. —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416-. (canceled)1861-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.66. (canceled)67. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6870-. (canceled)71. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.73119-. (canceled)120. The ...

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Method and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 23.-. (canceled)4. The compound of claim 1 , wherein v is 1.5. The compound of claim 1 , wherein M is a covalent bond or a C-Calkyl.612.-. (canceled)13. The compound of claim 1 , wherein B is —CH(M-W)—CH—CH— claim 1 , —CH—CH(M-W)—CH— claim 1 , or —(CH)—CH—CH(M-W)—.1416.-. (canceled)1861.-. (canceled)62. A compound of Table 3A or Table 3B claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , or prodrug thereof.63. (canceled)64. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , in an amount effective to treat or prevent an amyloid related disease.65. The method according to claim 64 , wherein said amyloid-related disease is Alzheimer's disease claim 64 , cerebral amyloid angiopathy claim 64 , inclusion body myositis claim 64 , macular degeneration claim 64 , MCI claim 64 , or Down's syndrome.67. (canceled)68. The method according to claim 64 , wherein said amyloid-related disease is diabetes claim 64 , AA amyloidosis claim 64 , AL amyloidosis claim 64 , ATTR-related amyloidosis claim 64 , or hemodialysis related amyloidosis (βM).6971.-. (canceled)72. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 17 , comprising administering to said subject a therapeutic compound of claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , in an amount effective to treat or prevent an amyloid related disease.73. A method for treating or preventing an amyloid-related disease in a subject in need thereof claim 62 , comprising administering to said subject a therapeutic compound of claim 62 , or pharmaceutically acceptable salts thereof claim 62 , in an amount effective to treat or prevent an amyloid related disease.74120.-. ( ...

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Compounds for the treatment of CNS and amyloid associated diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 1232-. (canceled)234. The compound of claim 233 , wherein Ris hydrogen.235. The compound of claim 233 , wherein Ris straight chain alkyl.236. The compound of claim 233 , wherein Ris t-butyl.237. The compound of claim 233 , wherein Ris carbocyclic.238. The compound of claim 233 , wherein Ris C-Cbicycloalkyl.239. The compound of claim 233 , wherein said bicyclic fused ring group is indolyl.240. The compound of claim 233 , wherein Lis CHCHor absent.251. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of in an amount effective to treat or prevent an amyloid related disease.252. The method according to claim 251 , wherein said amyloid-related disease is Alzheimer's disease claim 251 , cerebral amyloid angiopathy claim 251 , inclusion body myositis claim 251 , macular degeneration claim 251 , MCI claim 251 , or Down's syndrome.253. The method according to claim 251 , wherein amyloid fibril formation or deposition claim 251 , neurodegeneration claim 251 , microglial inflammatory response claim 251 , or cellular toxicity is reduced or inhibited upon administration of said compound.254. The method according to claim 251 , wherein said amyloid-related disease is diabetes claim 251 , AA amyloidosis claim 251 , AL amyloidosis claim 251 , or hemodialysis related amyloidosis (βM).255. The method of claim 251 , wherein said subject has Alzheimer's disease claim 251 , Mild Cognitive Impairment claim 251 , or cerebral amyloid angiopathy claim 251 , and stabilization of cognitive function claim 251 , prevention of a further decrease in cognitive function claim 251 , or prevention claim 251 , slowing claim 251 , or stopping of disease progression occurs in said patient upon administration.256. A method for inhibiting amyloid deposition in a subject comprising administering ...

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 5. A method for treating Alzheimer's disease claim 1 , mild cognitive impairment claim 1 , Down's syndrome claim 1 , Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type claim 1 , cerebral amyloid angiopathy claim 1 , a degenerative dementia claim 1 , a dementia of mixed vascular and degenerative origin claim 1 , dementia associated with Parkinson's disease claim 1 , dementia associated with progressive supranuclear palsy claim 1 , dementia associated with cortical basal degeneration claim 1 , or diffuse Lewy body type of Alzheimer's disease claim 1 , comprising administering a therapeutically effective amount of a compound of to a human subject in need thereof.6. The method of claim 5 , which is for treating Alzheimer's disease claim 5 , mild cognitive impairment claim 5 , cerebral amyloid angiopathy claim 5 , or degenerative dementia.7. The method of claim 6 , which is for treating Alzheimer's disease.8. The method of wherein the compound is administered intratracheally claim 5 , intranasally claim 5 , ontologically claim 5 , rectally claim 5 , vaginally claim 5 , or orally.9. A pharmaceutical composition comprising a compound of together with a pharmaceutically acceptable carrier.10. The pharmaceutical composition of which is suitable for oral administration.11. The pharmaceutical composition of claim 9 , which is in the form of a hard shell gelatin capsule claim 9 , soft shell gelatin capsule claim 9 , cachet claim 9 , pill claim 9 , tablet claim 9 , lozenge claim 9 , powder claim 9 , granule claim 9 , pellet claim 9 , dragee claim 9 , which is ...

METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease 112-. (canceled)14. The compound of claim 13 , wherein aais valine and aais absent.15. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of and a pharmaceutically acceptable carrier.17. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.18. The pharmaceutical composition of in a form suitable for oral administration.19. The pharmaceutical composition of claim 18 , which is in the form of a hard shell gelatin capsule claim 18 , soft shell gelatin capsule claim 18 , cachet claim 18 , pill claim 18 , tablet claim 18 , lozenge claim 18 , powder claim 18 , granule claim 18 , pellet claim 18 , dragee claim 18 , each of which is optionally enteric coated; a solution; an aqueous liquid suspension; a non-aqueous liquid suspension; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; an elixir; a syrup; or a pastille.20. The pharmaceutical composition of claim 19 , which is in the form of a hard shell gelatin capsule claim 19 , soft shell gelatin capsule claim 19 , or an enterically coated capsule. This application is a continuation of U.S. patent application Ser. No. 15/293,965, filed Oct. 14, 2016, now allowed, which is a continuation of U.S. patent application Ser. No. 14/246,894, filed Apr. 7, 2014, now U.S. Pat. No. 9,499,480, which is a continuation of U.S. patent application Ser. No. 11/871,639, filed Oct. 12, 2007, now U.S. Pat. No. 8,748,656, which claims priority to U.S. Provisional Patent Application No. 60/851,039, filed Oct. 12, 2006, and U.S. Provisional Patent ...

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either or . Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Compounds for the treatment of cns and amyloid associated diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease Pn particular, modified blood bram barrier (BBB) vectors such as phenylalanine derivatives are described as to provide parameters to select CNS drug candidates designated to penetrate the bram using a specific active transporter.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Methods and compositions for treating amyloid-related diseases

Abstract Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Un compuesto de Fórmula IV, o una de sus sales farmacéuticamente aceptables o solvatos: en donde: aa1 es un residuo de aminoácido natural o no natural; aa2 es un residuo de aminoácido natural o no natural, o está ausente; en donde dichos aa1 y aa2 son cada uno independientemente residuos de aminoácido de Fórmula VI: en donde: R1 se selecciona del grupo que consiste en un grupo sustituido o no sustituido seleccionado de alquilo C1-C12, alquenilo C2-C12, alquinilo C2-C12, cicloalquilo C3-C15; R2 es hidrógeno R3 es hidrógeno; o R3 es un enlace entre dos residuos de aminoácido, cuando están presentes dos residuos de aminoácido; R4 se selecciona del grupo que consiste en H y un grupo sustituido o no sustituido seleccionado de alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6; y n es 1, 2 o 3; en donde el término sustituido cuando está asociado con cualquiera de los grupos precedentes se refiere a un grupo sustituido en una o más posiciones con sustituyentes seleccionados de amino simple, mono y dialquilamino, mono y diarilamino, y alquilarilamino, acilamino incluyendo carbamoílo, y ureido, aminocarbonilo, mono y dialquilaminocarbonilo, ciano, azido, halógeno, hidroxilo, nitro, trifluorometilo, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, alcoxi C1-C6, ariloxi, benciloxi, bencilo, guanidino, imino y formilo; con la condición de que cuando R2 sea H y R3 sea H o un enlace, entonces R1 no sea un grupo -CH2fenilo. A compound of Formula IV, or a pharmaceutically acceptable salt or solvate thereof: wherein: aa1 is a natural or non-natural amino acid residue; aa2 is a natural or unnatural amino acid residue, or is absent; wherein said aa1 and aa2 are each independently amino acid residues of Formula VI: wherein: R1 is selected from the group consisting of a substituted or unsubstituted group selected from C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl , C3-C15 cycloalkyl; R2 is hydrogen R3 is hydrogen; or R3 is a link between ...

Methods and compositions for treating amyloid-related diseases

Disclosed are compounds of formula V wherein A is NH or oxygen and aa is a natural or unnatural amino acid residue and the remaining substituents are as defined in the specification, and their use in treating amyloid-related diseases such as Alzheimer's disease, cognitive impairment and Down's syndrome. (62) (62) Divided Out of 544684

Methods and compositions for treating amyloid-related diseases

Compounds of formulae (VIII), (IX), (X), (XI), (XII) (XIII), (XIV) and (XV), in which the variables are as defined in the claims are described, as well as methods, pharmaceutical compositions and kits for treating or preventing amyloid-related disease.

Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy

Postopki, spojine, sestavki in vehikli za dostavljanje 3-amino-1- propansulfonske kisline

Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi

Metodai, junginiai, kompozicijos ir transporteriai, skirti 3- amino-1- propansulfonrūgšties pristatymui

Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre

Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico

La invención se refiere a métodos, compuestos, composiciones y vehículos para administrar ácido 3-amino-1-propanosulfónico (3APS) en un sujeto, preferiblemente un sujeto humano. La invención abarca compuestos que producirán o generarán 3APS, ya sea in vitro o in vivo. Los compuestos preferidos incluyen profármacos de aminoácidos de 3APS para su uso, incluyendo, entre otros, la prevención y el tratamiento de la enfermedad de Alzheimer. (Traducción automática con Google Translate, sin valor legal)

Methods and compositions for treating amyloid-related diseases